


Preliminary Amendment

Patent Case: CD0787Q1 2

Claims 1-7 (canceled)

Claim 8 (previously presented) A crystalline polymorph Form I of the compound represented by the formula I



and characterized by at least one of the following properties:

- a melting point range of about 164 to about 165°C wherein the melting point range is determined using USP Class Ia procedure;
- a specific rotation equal to  $[\alpha]^{25}_D = -29.4^\circ$  wherein the specific rotation is determined using a concentration of 10 mg/ml in methanol;
- an X-ray powder diffraction pattern substantially similar to that presented in Figure 1;
- a differential scanning calorimetry thermogram substantially similar to that presented in Figure 7; or
- a proton NMR spectrum substantially similar to that presented in Figure 10.

Claims 9 and 10 (canceled)

Claim 11 (previously presented) A pharmaceutical composition comprising an anti-fungally effective amount of the crystalline polymorph form I of claim 8 and a pharmaceutically acceptable carrier.

Claims 12 and 13 (canceled)


Claim 14 (previously presented) A method of treating and/or preventing fungal infections in a mammal which comprises administering to said mammal an anti-fungally effective amount of the crystalline polymorph form I of claim 8.

Preliminary Amendment

Patent Case: CD0787Q1 3

Claims 15-18 (Canceled)

Claim 19 (previously presented) A crystalline polymorph Form III of the compound represented by the formula I



and characterized by an X-ray powder diffraction pattern displaying d spacing peaks at 28.69, 14.45, 10.59, 7.27, 6.59, 4.14, 3.58, and 3.53 +/-0.04.

Claim 20 (previously presented) The crystalline polymorph Form III of Claim 19 further characterized by an X-ray powder diffraction pattern substantially similar to that presented in Figure 3.

Claim 21 (previously presented) A pharmaceutical composition comprising an anti-fungally effective amount of the crystalline polymorph Form III of Claim 19 and a pharmaceutically acceptable carrier.

Claim 22 (previously presented) A method of treating and/or preventing fungal infections in a mammal which comprises administering to said mammal an anti-fungally effective amount of the crystalline polymorph Form III of Claim 19.